MGC Pharmaceuticals Ltd’s (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) major clinical trial programs planned for CimetrA™, CannEpil® and CogniCann® in 2021 are actively progressing across Australia, Israel and Brazil.
Commencement of the CimetrA Phase III to treat COVID-19 and CannEpil Phase IIb trials for treatment-resistant epilepsy are imminent and all the required regulatory approvals have been received for both.
